Breast Adenocarcinoma, Breast Cancer, Breast Cancer in Situ, Breast Cancer Invasive, Breast Cancer Stage, Breast Cancer Stage IV, Breast Neoplasms
Conditions
Keywords
Transgender, Breast Cancer, Nonbinary, Gender Diverse, Gender-Affirming Hormone Therapy
Brief summary
There is no granular retrospective data on breast cancer in transgender and gender-diverse (TGD) persons from a contemporary and diverse American cohort. The purpose of this investigation is to aggregate data from multiple institutions to describe the risk, diagnosis, management, and outcomes of TGD persons with breast cancer in effort to identify opportunities for future intervention studies to eliminate breast cancer disparities for this population.
Interventions
None listed
Sponsors
Medical College of Wisconsin
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 years of age or older 2. Breast cancer diagnosis (including DCIS) 3. Persons who identify as gender and/or sex that is different from the sex they were assigned at birth
Exclusion criteria
1. Age \<18 at time of breast cancer diagnosis 2. Cis-gendered persons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Breast Cancer Diagnosis Method | 33 years | Describe the method of breast cancer diagnosis (self detected vs screen detected vs healthcare provider detected) and compare to the published data from cisgender women by determining means and standard deviation and comparing rates using the Wilcoxon signed-rank test. |
| Breast Cancer Risk Factors | 33 years | Assess breast cancer risk factors (family history, genetics, etc.), including a prior use of gender-affirming hormone therapy and/or gender-affirming surgery on tumor receptor status and stage at diagnosis using t-test and chi-squared test. |
| Breast Cancer Management Strategies | 33 years | Report breast cancer management strategies (type of breast surgery, receipt of radiation, etc.) through descriptive and comparative staststics with a focus on the use of adjuvant endocrine therapy and gender-affirming hormone therapy for patients with hormone-receptor positive disease using t-test and chi-squared test. |
| Outcomes Data | 33 years | Breast cancer local and distant recurrence, overall survival, and disease-free survival using Kaplan-Meier analysis. Cox Proportional Hazards model will be used to estimate the effect of various factors on distant metastasis-free and overall survival. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORChandler S Cortina
The Medical College of Wisconsin
Outcome results
None listed